TRENDS

Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020

March 13, 2018
By Reiji Anasako Eisai’s mega-scale collaboration deal with US Merck on its cancer drug Lenvima (lenvatinib) could pull the Japanese drug maker out of the post-Aricept (donepezil)/Pariet (rabeprazole) doldrums and help it achieve the ambitious 800 billion yen sales target…

To read the full story

Related Article

TRENDS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…